{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:05:59Z","timestamp":1784531159797,"version":"3.55.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT \/PR59928\/ BSA \/33\/643\/2025"],"award-info":[{"award-number":["BT \/PR59928\/ BSA \/33\/643\/2025"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.micpath.2026.108627","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:28:47Z","timestamp":1781159327000},"page":"108627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advancing protozoan vaccine research: A review of promising candidates and emerging technologies"],"prefix":"10.1016","volume":"218","author":[{"given":"Madhusmita","family":"Subudhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srimathi","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-2036","authenticated-orcid":false,"given":"Paresh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2026.108627_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-4017(94)90090-6","article-title":"Vaccination against animal parasites","volume":"54","author":"Lightowlers","year":"1994","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1017\/S0031182013002060","article-title":"Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs","volume":"141","author":"McAllister","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2026.108627_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.vetpar.2011.05.036","article-title":"Developing vaccines to control protozoan parasites in ruminants: dead or alive?","volume":"180","author":"Innes","year":"2011","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1020029","article-title":"Protozoan co-infections and parasite influence on the efficacy of vaccines against bacterial and viral pathogens","volume":"13","author":"Akoolo","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11845-022-02998-9","article-title":"Toxoplasma gondii vaccine candidates: a concise review","volume":"192","author":"Mamaghani","year":"2023","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.micpath.2026.108627_bib6","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.3390\/ijms20225748","article-title":"An overview of drug resistance in protozoal diseases","volume":"20","author":"Capela","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.micpath.2026.108627_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1471-4922(02)02289-4","article-title":"How protozoan parasites evade the immune response","volume":"18","author":"Zambrano-Villa","year":"2002","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/ni.2853","article-title":"Vaccines against tropical parasitic diseases: a persisting answer to a persisting problem","volume":"15","author":"Sacks","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fimmu.2020.00204","article-title":"The delay in the licensing of protozoal vaccines: a comparative history","volume":"11","author":"Palatnik-de-Sousa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","article-title":"Malaria vaccines: progress to date","volume":"37","author":"Stanisic","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.micpath.2026.108627_bib11","article-title":"A systematic review of historical and current trends in chagas disease","volume":"8","author":"\u00c1lvarez-Hern\u00e1ndez","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.it.2012.02.001","article-title":"Whole parasite vaccination approaches for prevention of malaria infection","volume":"33","author":"Butler","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pt.2021.11.004","article-title":"Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases","volume":"38","author":"Solana","year":"2022","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib14","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"Lyke","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.micpath.2026.108627_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"Suppl 4","key":"10.1016\/j.micpath.2026.108627_bib16","doi-asserted-by":"crossref","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","article-title":"The March toward malaria vaccines","volume":"33","author":"Hoffman","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/978-1-0716-1884-4_28","article-title":"Plasmodium falciparum antigen expression in Leishmania parasite: a way forward for live attenuated vaccine development","volume":"2410","author":"Srivastava","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.micpath.2026.108627_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12936-016-1435-y","article-title":"Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity","volume":"15","author":"Hickey","year":"2016","journal-title":"Malar. J."},{"key":"10.1016\/j.micpath.2026.108627_bib19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.vaccine.2006.09.074","article-title":"A review of human vaccine research and development: malaria","volume":"25","author":"Girard","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41541-022-00563-0","article-title":"Toxoplasmosis vaccines: what we have and where to go?","volume":"7","author":"Zhang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4161\/hv.22474","article-title":"Development of Toxoplasma gondii vaccine: a global challenge","volume":"9","author":"Verma","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2026.108627_bib22","article-title":"Toxoplasma gondii gra5 deletion mutant protects hosts against Toxoplasma gondii infection and breast tumors","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40249-023-01109-9","article-title":"A live attenuated RH\u0394ompdc\u0394uprt mutant of Toxoplasma gondii induces strong protective immunity against toxoplasmosis in mice and cats","volume":"12","author":"Shen","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.micpath.2026.108627_bib24","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3389\/fmicb.2019.01875","article-title":"Immunization with a live-attenuated RH:\u0394NPT1 strain of Toxoplasma gondii induces strong protective immunity against toxoplasmosis in mice","volume":"10","author":"Yang","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fimmu.2017.00730","article-title":"Immunization with Toxoplasma gondii GRA17 deletion mutant induces partial protection and survival in challenged mice","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib26","article-title":"Advances in Toxoplasma gondii vaccines: current strategies and challenges for vaccine development","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.micpath.2026.108627_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.1700674","article-title":"Live attenuated Leishmania donovani centrin gene-deleted parasites induce IL-23-Dependent IL-17-Protective immune response against visceral leishmaniasis in a murine model","volume":"200","author":"Banerjee","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3389\/fimmu.2017.01788","article-title":"Immunization with live attenuated Leishmania donovani Centrin-\/- parasites is efficacious in asymptomatic infection","volume":"8","author":"Ismail","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41541-022-00574-x","article-title":"Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis","volume":"7","author":"Karmakar","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.70.1.62-68.2002","article-title":"Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination","volume":"70","author":"Papadopoulou","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2026.108627_bib31","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.4049\/jimmunol.1202801","article-title":"Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB\/c mice","volume":"190","author":"Dey","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/14760584.2015.989989","article-title":"Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease","volume":"14","author":"S\u00e1nchez-Vald\u00e9z","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0928-8244(03)00256-6","article-title":"Phytomonas serpens, a tomato parasite, shares antigens with Trypanosoma cruzi that are recognized by human sera and induce protective immunity in mice","volume":"39","author":"Bregan\u00f3","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4049\/jimmunol.2300509","article-title":"Memory-like NK cells are a critical component of vaccine-induced immunity to Trypanosoma cruzi infection","volume":"212","author":"Horta","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00908-19","article-title":"Induction of effective immunity against Trypanosoma cruzi","volume":"88","author":"Williams","year":"2020","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2026.108627_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0264-410X(97)84509-4","article-title":"Phenotypic and genotypic alterations associated with the attenuation of a Theileria annulata vaccine cell line from Turkey","volume":"16","author":"Somerville","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s004360050179","article-title":"A preliminary study on the attenuation of Tunisian schizont-infected cell lines of Theileria annulata","volume":"82","author":"Darghouth","year":"1996","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.micpath.2026.108627_bib38","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1038\/s41598-024-57325-2","article-title":"Isolation and propagation of an Egyptian Theileria annulata infected cell line and evaluation of its use as a vaccine to protect cattle against field challenge","volume":"14","author":"Al-Hosary","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2026.108627_bib39","article-title":"Population genetic analysis of the Theileria annulata parasites identified limited diversity and multiplicity of infection in the vaccine from India","volume":"11","author":"Roy","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib40","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00436-023-07912-5","article-title":"Comparative evaluation of cell-mediated immune response in calves immunized with live-attenuated and killed Theileria annulata vaccines","volume":"122","author":"Ramzan","year":"2023","journal-title":"Parasitol. Res."},{"issue":"Suppl 6","key":"10.1016\/j.micpath.2026.108627_bib41","doi-asserted-by":"crossref","first-page":"G14","DOI":"10.1016\/j.vaccine.2008.10.001","article-title":"Vaccination of cattle against tropical theileriosis in Uzbekistan using autochthonous live vaccine","volume":"26","author":"Rasulov","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib42","article-title":"Safety and efficacy of the east Coast fever muguga cocktail vaccine: a systematic review","volume":"9","author":"Allan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.micpath.2026.108627_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12917-019-1787-y","article-title":"Infection and treatment method (ITM) vaccine against East Coast fever: reducing the number of doses per straw for use in smallholder dairy herds by thawing, diluting and refreezing already packaged vaccine","volume":"15","author":"Patel","year":"2019","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.micpath.2026.108627_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.parint.2017.11.004","article-title":"Bovine babesiosis: cattle protected in the field with a frozen vaccine containing Babesia bovis and Babesia bigemina cultured in vitro with a serum-free medium","volume":"67","author":"Rojas-Mart\u00ednez","year":"2018","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.micpath.2026.108627_bib45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fvets.2020.00364","article-title":"An overview of current knowledge on in vitro babesia cultivation for production of live attenuated vaccines for bovine babesiosis in Mexico","volume":"7","author":"Alvarez","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.micpath.2026.108627_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219913","article-title":"Vaccination with an in vitro culture attenuated Babesia bovis strain safely protects highly susceptible adult cattle against acute bovine babesiosis","volume":"14","author":"Bastos","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.addr.2018.06.025","article-title":"Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases","volume":"145","author":"Tao","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.micpath.2026.108627_bib48","article-title":"Precision-engineering of subunit vaccine particles for prevention of infectious diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria vaccines: recent advances and new Horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"22","key":"10.1016\/j.micpath.2026.108627_bib50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","article-title":"Malaria vaccines: a new era of prevention and control","author":"Duffy","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156588","article-title":"RTS,S: the first malaria vaccine","volume":"132","author":"Zavala","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.micpath.2026.108627_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (MosquirixTM): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2026.108627_bib53","article-title":"WHO recommends second vaccine for malaria prevention in children","author":"Mahase","year":"2023","journal-title":"Br. Med. J."},{"key":"10.1016\/j.micpath.2026.108627_bib54","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib55","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/s44321-024-00131-0","article-title":"Whole-sporozoite malaria vaccines: where we are, where we are going","volume":"16","author":"Moita","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.micpath.2026.108627_bib56","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1038\/s41467-021-26118-w","article-title":"Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination","volume":"12","author":"Larsen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108627_bib57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciy1140","article-title":"First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, A vaccine candidate to prevent pregnancy-associated malaria","volume":"69","author":"Mordm\u00fcller","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib58","article-title":"Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine","author":"MacMillen","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.micpath.2026.108627_bib59","article-title":"Development and qualification of an antigen integrity assay for a Plasmodium falciparum malaria transmission blocking vaccine candidate, Pfs230","volume":"10","author":"Miura","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.micpath.2026.108627_bib60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1756-3305-6-34","article-title":"Induction of long-lasting protective immunity against Toxoplasma gondii in BALB\/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles","volume":"6","author":"Chuang","year":"2013","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.micpath.2026.108627_bib61","first-page":"1","article-title":"Sustained release of recombinant surface antigen 2 (rSAG2) from poly(lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice","author":"Chuang","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.micpath.2026.108627_bib62","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fmicb.2016.00609","article-title":"Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute toxoplasmosis in BALB\/c mice","volume":"7","author":"Ching","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib63","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-017-0025-5","article-title":"A defined subunit vaccine that protects against vector-borne visceral leishmaniasis","volume":"2","author":"Duthie","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molimm.2021.11.009","article-title":"Immunological characterization of rLdTCP1\u03b3 for its prophylactic potential against visceral leishmaniasis in hamster model","volume":"141","author":"Anand","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib66","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/jcb.26719","article-title":"Exploring sand fly salivary proteins to design multiepitope subunit vaccine to fight against visceral leishmaniasis","volume":"120","author":"Pandey","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.micpath.2026.108627_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fimmu.2012.00099","article-title":"Vaccine development against Leishmania donovani","volume":"3","author":"Das","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib68","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/pim.12356","article-title":"Evaluation of a novel lentiviral vaccine expressing KMP11-HASPB fusion protein against Leishmania infantum in BALB\/c mice","volume":"38","author":"Mortazavidehkordi","year":"2016","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/mp2002494","article-title":"Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route","volume":"9","author":"Ravindran","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.micpath.2026.108627_bib70","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/20477724.2020.1842976","article-title":"Design of a multi-epitope subunit vaccine for immune-protection against Leishmania parasite","volume":"114","author":"Yadav","year":"2020","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.micpath.2026.108627_bib71","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41541-023-00782-z","article-title":"Subunit nanovaccine elicited T cell functional activation controls Trypanosoma cruzi mediated maternal and placental tissue damage and improves pregnancy outcomes in mice","volume":"8","author":"Rios","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib72","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1574-695X.2007.00251.x","article-title":"Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice","volume":"50","author":"Sanchez-Burgos","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib73","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1016\/j.vaccine.2015.07.017","article-title":"Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice","volume":"33","author":"Martinez-Campos","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib74","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1080\/21645515.2015.1119346","article-title":"A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB\/c mouse model of Chagas disease","volume":"12","author":"Barry","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2026.108627_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007413","article-title":"A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection","volume":"13","author":"Barry","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006240","article-title":"Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico","volume":"12","author":"Villanueva-Lizama","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib77","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.vaccine.2015.01.044","article-title":"Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease","volume":"33","author":"Bontempi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib78","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2217\/imt-2017-0009","article-title":"Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi","volume":"9","author":"Bontempi","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.micpath.2026.108627_bib79","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/0074-02760140440","article-title":"Reaching for the Holy Grail: insights from infection\/cure models on the prospects for vaccines for Trypanosoma cruzi infection","volume":"110","author":"Bustamante","year":"2015","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.micpath.2026.108627_bib80","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1749-6632.1998.tb11054.x","article-title":"Different vaccine strategies used to protect against Theileria annulata","volume":"849","author":"Boulter","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.micpath.2026.108627_bib81","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0264-410X(97)00197-7","article-title":"Induction of protective immunity to Theileria annulata using two major merozoite surface antigens presented by different delivery systems","volume":"15","author":"d'Oliveira","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib82","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0304-4017(01)00557-X","article-title":"Advances and prospects for subunit vaccines against protozoa of veterinary importance","volume":"101","author":"Jenkins","year":"2001","journal-title":"Vet. Parasitol."},{"issue":"Suppl 1","key":"10.1016\/j.micpath.2026.108627_bib83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/tbed.13374","article-title":"The protection afforded to cattle immunized with Theileria annulata infected cell line is enhanced by subunit vaccine candidate TaSP","volume":"67","author":"Saaid","year":"2020","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib84","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.vaccine.2004.09.039","article-title":"Subunit vaccine based on the p67 major surface protein of Theileria parva sporozoites reduces severity of infection derived from field tick challenge","volume":"23","author":"Musoke","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib85","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.vaccine.2022.01.023","article-title":"Babesia bovis AMA-1, MSA-2c and RAP-1 contain conserved B and T-cell epitopes, which generate neutralizing antibodies and a long-lasting Th1 immune response in vaccinated cattle","volume":"40","author":"Hidalgo-Ruiz","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib86","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vetpar.2010.06.024","article-title":"A Babesia bovis gene syntenic to Theileria parva p67 is expressed in blood and tick stage parasites","volume":"173","author":"Freeman","year":"2010","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.molbiopara.2004.02.006","article-title":"A Babesia bovis merozoite protein with a domain architecture highly similar to the thrombospondin-related anonymous protein (TRAP) present in Plasmodium sporozoites","volume":"136","author":"Gaffar","year":"2004","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib88","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.parint.2010.03.004","article-title":"Babesia bovis expresses a neutralization-sensitive antigen that contains a microneme adhesive repeat (MAR) domain","volume":"59","author":"Silva","year":"2010","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.micpath.2026.108627_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetpar.2020.109275","article-title":"Characterization of GASA-1, a new vaccine candidate antigen of Babesia bovis","volume":"287","author":"Flores","year":"2020","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib90","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.micpath.2026.108627_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256980","article-title":"A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-na\u00efve adults","volume":"16","author":"Sklar","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2026.108627_bib92","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1999.1050","article-title":"Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms","volume":"261","author":"Nagata","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.micpath.2026.108627_bib93","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.exppara.2009.02.010","article-title":"Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity","volume":"122","author":"Doba\u00f1o","year":"2009","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib94","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/hv.3.2.3833","article-title":"Reduced production of RNA transcripts from individual DNA plasmids given in a multivalent DNA vaccine formula","volume":"3","author":"Bacon","year":"2007","journal-title":"Hum. Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib95","article-title":"Effective functional immunogenicity of a DNA vaccine combination delivered via in vivo electroporation targeting malaria infection and transmission","volume":"10","author":"Cao","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.micpath.2026.108627_bib96","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ncomms1615","article-title":"The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody","volume":"2","author":"Douglas","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2026.108627_bib97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","article-title":"A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys","volume":"17","author":"Douglas","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.micpath.2026.108627_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041223","article-title":"Establishment of an antiplasmodial vaccine based on PfRH5-Encoding RNA replicons stabilized by Cationic liposomes","volume":"15","author":"Fotoran","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2026.108627_bib99","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/s41598-020-60551-z","article-title":"Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination","volume":"10","author":"Bailey","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.micpath.2026.108627_bib100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4161\/hv.26703","article-title":"Toxoplasma gondii: immune response and protective efficacy induced by ROP16\/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2","volume":"10","author":"Liu","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2026.108627_bib101","article-title":"A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice","volume":"14","author":"Li","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2026.108627_bib102","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12879-020-05220-2","article-title":"Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50 V and determination of its protective efficacy against acute toxoplasmosis","volume":"20","author":"\u015eahar","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib103","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1586\/14760584.7.6.833","article-title":"FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine","volume":"7","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.micpath.2026.108627_bib104","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fimmu.2012.00069","article-title":"Vaccines for canine leishmaniasis","volume":"3","author":"Palatnik-de-Sousa","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib106","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3389\/fimmu.2018.02420","article-title":"Heterologous immunization with defined RNA and subunit vaccines enhances T cell responses that protect against Leishmania donovani","volume":"9","author":"Duthie","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007880","article-title":"Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model","volume":"4","author":"Sachdeva","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.micpath.2026.108627_bib108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molimm.2018.03.004","article-title":"Immunomodulation induced through ornithine decarboxylase DNA immunization in Balb\/c mice infected with Leishmania donovani","volume":"97","author":"Kumar","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib109","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jir842","article-title":"Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis","volume":"205","author":"Maroof","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib110","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","article-title":"Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan","volume":"29","author":"Younis","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.micpath.2026.108627_bib111","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/978-1-4939-3389-1_44","article-title":"Attenuated Salmonella sp. as a DNA delivery System for Trypanosoma cruzi antigens","volume":"1404","author":"Bivona","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.micpath.2026.108627_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.565142","article-title":"Cruzipain and its physiological inhibitor, chagasin, as a DNA-Based therapeutic vaccine against Trypanosoma cruzi","volume":"11","author":"Cerny","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib113","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/21645515.2015.1078044","article-title":"Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection","volume":"12","author":"Cerny","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.micpath.2026.108627_bib114","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/infdis\/jiu480","article-title":"Oral multicomponent DNA vaccine delivered by attenuated Salmonella elicited immunoprotection against American trypanosomiasis","volume":"211","author":"Cazorla","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.micpath.2026.108627_bib115","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.vaccine.2016.05.011","article-title":"A prime-boost immunization with Tc52 N-terminal domain DNA and the recombinant protein expressed in Pichia pastoris protects against Trypanosoma cruzi infection","volume":"34","author":"Matos","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib116","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.micinf.2007.11.010","article-title":"Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein","volume":"10","author":"Chou","year":"2008","journal-title":"Microb. Infect."},{"key":"10.1016\/j.micpath.2026.108627_bib117","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3389\/fimmu.2019.01456","article-title":"TcG2\/TcG4 DNA vaccine induces Th1 immunity against acute Trypanosoma cruzi infection: adjuvant and antigenic effects of heterologous T. rangeli booster immunization","volume":"10","author":"Gupta","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108627_bib118","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.vetimm.2008.03.009","article-title":"Orientation of bovine CTL responses towards PIM, an antibody-inducing surface molecule of Theileria parva, by DNA subunit immunization","volume":"124","author":"Ververken","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.micpath.2026.108627_bib119","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.vaccine.2019.02.009","article-title":"Gene Gun DNA immunization of cattle induces humoral and CD4 T-cell-mediated immune responses against the Theileria parva polymorphic immunodominant molecule","volume":"37","author":"Fry","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2026.108627_bib120","article-title":"Characterization of a novel chimeric Theileria parva p67 antigen which incorporates into virus-like particles and is highly immunogenic in mice","volume":"10","author":"Whittle","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.micpath.2026.108627_bib121","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1515\/ap-2018-0042","article-title":"Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster","volume":"63","author":"Wang","year":"2018","journal-title":"Acta Parasitol."},{"key":"10.1016\/j.micpath.2026.108627_bib122","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1186\/s13071-016-1862-1","article-title":"A recombinant multi-antigen vaccine formulation containing Babesia bovis merozoite surface antigens MSA-2a1, MSA-2b and MSA-2c elicits invasion-inhibitory antibodies and IFN-\u03b3 producing cells","volume":"9","author":"Gimenez","year":"2016","journal-title":"Parasites Vectors"}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026003530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026003530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:40:00Z","timestamp":1784529600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401026003530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":122,"alternative-id":["S0882401026003530"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108627","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing protozoan vaccine research: A review of promising candidates and emerging technologies","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108627"}}